Fumihiro Tanaka

12.3k total citations · 2 hit papers
404 papers, 8.7k citations indexed

About

Fumihiro Tanaka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Fumihiro Tanaka has authored 404 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Pulmonary and Respiratory Medicine, 166 papers in Oncology and 85 papers in Surgery. Recurrent topics in Fumihiro Tanaka's work include Lung Cancer Diagnosis and Treatment (103 papers), Lung Cancer Treatments and Mutations (101 papers) and Pleural and Pulmonary Diseases (52 papers). Fumihiro Tanaka is often cited by papers focused on Lung Cancer Diagnosis and Treatment (103 papers), Lung Cancer Treatments and Mutations (101 papers) and Pleural and Pulmonary Diseases (52 papers). Fumihiro Tanaka collaborates with scholars based in Japan, United States and China. Fumihiro Tanaka's co-authors include Hiromi Wada, Hidetaka Uramoto, Kazuhiro Yanagihara, Ryo Miyahara, Kazue Yoneda, Yosuke Otake, Seiki Hasegawa, Yozo Kawano, Kazumasa Takenaka and Mio Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Fumihiro Tanaka

382 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recurrence after surgery in patients with NSCLC.

2014 423 citations Hidetaka Uramoto, Fumihiro Tanaka PubMed profile →
Thoracic and cardiovascular surgery in Japan during 2014

2016 267 citations Fumihiro Tanaka et al. profile →

Peers

Countries citing papers authored by Fumihiro Tanaka

Since Specialization

Citations

This map shows the geographic impact of Fumihiro Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumihiro Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumihiro Tanaka more than expected).

Fields of papers citing papers by Fumihiro Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumihiro Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumihiro Tanaka. The network helps show where Fumihiro Tanaka may publish in the future.

Co-authorship network of co-authors of Fumihiro Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Fumihiro Tanaka. A scholar is included among the top collaborators of Fumihiro Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumihiro Tanaka. Fumihiro Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study 2024 ·Annals of Oncology ·Mariano Provencio, Mark M. Awad, Tina Cascone, (unknown), Jie He, Shun Lü, Aurelia Alexandru, (unknown), Robin Cornelissen, Lía Raquel Oliveira, (unknown), J-L. Pujol, (unknown), Jhanelle E. Gray, C. Coronado Erdmann, (unknown), (unknown), (unknown), Fumihiro Tanaka	9
2	LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study 2024 ·ESMO Open ·Mark M. Awad, Tina Cascone, Jonathan Spicer, Jie He, Shun Lü, Fumihiro Tanaka, Robin Cornelissen, (unknown), (unknown), Luboš Petruželka, Lin Wu, J-L. Pujol, Hiroyuki Ito, T-E. Ciuleanu, (unknown), Annelies Janssens, C. Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, Mariano Provencio	2
3	Association of Preoperative Rehabilitation With Postoperative Length of Hospital Stay for Elderly Lung Cancer Patients 2023 ·Journal of UOEH ·(unknown), (unknown), (unknown), Masaru Takenaka, Fumihiro Tanaka, Kiyohide Fushimi, Shinya Matsuda, Satoru Saeki	2
4	Estimation of the global burden of mesothelioma deaths from incomplete national mortality data 2017 ·Occupational and Environmental Medicine ·Odgerel Chimed‐Ochir, Ken Takahashi, Tom Sorahan, Tim Driscoll, Christina Fitzmaurice, (unknown), Kittisak Sawanyawisuth, Sugio Furuya, Fumihiro Tanaka, Seichi Horie, Nico van Zandwijk, Jukka Takala	107
5	EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’ 2016 ·Oncology Reports ·Yasuhiro Chikaishi, Kazue Yoneda, (unknown), Fumihiro Tanaka	47
6	A case of multiple calcifying fibrous tumors of the pleura 2014 ·The Journal of the Japanese Association for Chest Surgery ·(unknown), (unknown), (unknown), (unknown), Takeshi Hanagiri, Fumihiro Tanaka	1
7	The Safety Indicator of Radiotherapy for Advanced Hepatoma with Liver Cirrhosis 2013 ·Journal of Gastroenterology and Hepatology Research ·Shintaro Shirai, Morio Sato, Yasutaka Noda, (unknown), Tetsuo Sonomura, Nobuyuki Kawai, Hiroki Minamiguchi, Motoki Nakaï, (unknown), Fumihiro Tanaka	2
8	Six Cases of Lung Adenocarcinoma Successfully Treated Using Alternate Day Administration of Gefitinib 2013 ·Haigan ·Teruo Iwata, Taiji Kuwata, (unknown), Hidetaka Uramoto, Fumihiro Tanaka	1
9	Comparison of Therapeutic Effect of Miriplatin Suspension Versus Miriplatin Emulsion in Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: A Prospective Evaluation 2013 ·Journal of Gastroenterology and Hepatology Research ·(unknown), Nobuyuki Kawai, Morio Sato, Hiroki Minamiguchi, Motoki Nakaï, (unknown), Kouhei Nakata, Akira Ikoma, Fumihiro Tanaka, (unknown), Tetsuo Sonomura	0
10	A case of chondrosarcoma originating in the rib 2013 ·The Journal of the Japanese Association for Chest Surgery ·(unknown), Teruo Iwata, (unknown), Hidetaka Uramoto, Takeshi Hanagiri, Fumihiro Tanaka	0
11	Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. 2012 ·PubMed ·Hidetaka Uramoto, Tadaaki Yamada, Seiji Yano, (unknown), Seiki Hasegawa, Fumihiro Tanaka	23
12	Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients 2012 ·International Journal of Clinical Oncology ·Tetsuro Baba, (unknown), Koji Kuroda, Yoshiki Shigematsu, Yoshinobu Ichiki, Hidetaka Uramoto, Takeshi Hanagiri, Fumihiro Tanaka	11
13	The prognostic significance of HER2 overexpression in non-small cell lung cancer. 2011 ·PubMed ·Masaru Takenaka, Takeshi Hanagiri, Shinji Shinohara, Taiji Kuwata, Yasuhiro Chikaishi, (unknown), Yoshiki Shigematsu, Yoshika Nagata, Hidehiko Shimokawa, Makoto Nakagawa, Hidetaka Uramoto, Tomoko So, Fumihiro Tanaka	32
14	A case of Scimiter syndrome with pulmonary sequestration 2010 ·The Journal of the Japanese Association for Chest Surgery ·Masaki Hashimoto, (unknown), Yoshitomo Okumura, Nobuyuki Kondoh, Fumihiro Tanaka, Seiki Hasegawa	1
15	Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer 2008 ·Molecular Cancer Therapeutics ·(unknown), Eishi Ashihara, Shinya Kimura, Kazumasa Takenaka, Kiyoshi Sato, Ruriko Tanaka, Asumi Yokota, Yuri Kamitsuji, Miki Takeuchi, Junya Kuroda, Fumihiro Tanaka, Toshikazu Yoshikawa, Taira Maekawa	47
16	A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)—the 4th study 2004 ·Annals of Oncology ·Masatsugu Nakagawa, Fumihiro Tanaka, Noriaki Tsubota, Mitsuo Ohta, Motoshi Takao, Hiromi Wada	57
17	Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. 2003 ·PubMed ·Rajagopal Ramesh, Abner M. Mhashilkar, Fumihiro Tanaka, Yuji Saito, Cynthia D. Branch, Kerry Sieger, John B. Mumm, Alexis Stewart, (unknown), Laure Dumoutier, Elizabeth A. Grimm, Jean‐Christophe Renauld, Sergei V. Kotenko, Sunil Chada, (unknown)	160
18	Validity of Postoperative Adjuvant Chemotherapy for Non-small Cell Lung Cancer. 2002 ·Haigan ·Fumihiro Tanaka, Hiromi Wada	1
19	Paraganglioma of the posterior mediastinum: Value of magnetic resonance imaging 1992 ·The Annals of Thoracic Surgery ·Fumihiro Tanaka, (unknown), (unknown), Cheng-long Huang, (unknown), Mari Mino, Michimasa Matsuo, Kunio Ichijima	15
20	[Four cases of spontaneous pneumothorax with no reexpansion of collapsed lung despite chest tube drainage]. 1992 ·PubMed ·Fumihiro Tanaka, (unknown), (unknown), (unknown), (unknown), Masaya Ito, (unknown), Katsuya Shiraki, Hiroji Uemura	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact